MARVEL-TTAS
Phase 4
- Conditions
- Deep vein thrombosis
- Registration Number
- JPRN-jRCTs071180059
- Lead Sponsor
- Tsujita Kenichi
- Brief Summary
The purpose was to determine the appropriate effect of antithrombotic drugs using a new thrombogenicity assessment system (T-TAS) for pulmonary thromboembolism and deep vein thrombosis. However, the target number of cases was not reached, and analysis including the primary endpoint was difficult. The combination of the start of study enrollment and the outbreak of COVID-19 was a factor that made enrollment difficult.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
New onset case of venous thromboembolism and deep vein thrombosis, who requires permanent antithrombotic therapy
Exclusion Criteria
1. contraindication of apixaban usage
2. Patients who are already taking antithrombotic or thrombolytic therapies
3. Patients who are judged as an inappropriate case to enroll
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fluctuation of AR10-AU C30 value with or without bleeding events
- Secondary Outcome Measures
Name Time Method 1) Fluctuation of AR10-AUC30 value in the case of venous thromboembolism<br><br>2) Fluctuation of AR10-AUC30 value after the remission venous thromboembolism<br><br>3) All death<br><br>4) Other adverse events